Skip to main content

Table 5 Correlation between improvements (%) in lower urinary tract symptoms & female sexual function

From: The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study

  Desire Arousal Lubrication Orgasm Satisfaction Pain Total FSFI
rs P rs P rs P rs P rs P rs P rs P
Group A
 Frequency −0.088 0.553 0.220 0.298 − 0.201 0.171 − 0.237 0.104 0.015 0.918 − 0.105 0.479 − 0.254 0.081
 Urgency 0.168 0.253 0.041 0.781 −0.195 0.199 −0.240 0.135 0.035 0.815 0.013 0.928 −0.224 0.127
 Nocturia 0.209 0.154 0.157 0.286 −0.188 0.201 0.062 0.674 0.240 0.101 −0.054 0.714 0.181 0.219
 Incontinence −0.007 0.960 0.158 0.283 0.134 0.364 −0.270 0.064 0.101 0.496 −0.076 0.610 −0.026 0.858
 Pads −0.114 0.442 −0.076 0.607 −0.076 0.609 0.180 0.114 0.119 0.422 −0.128 0.384 −0.222 0.150
 Voided Volume 0.041 0.782 −0.067 0.651 −0.114 0.441 −0.010 0.948 0.228 0.119 0.126 0.393 0.077 0.603
Group B
 Frequency 0.103 0.545 −0.284 0.089 −0.429 0.008 0.139 0.413 −0.037 0.826 −0.230 0.170 −0.267 0.110
 Urgency 0.005 0.977 −0.002 0.991 0.163 0.335 −0.119 0.484 0.253 0.132 0.011 0.946 0.008 0.638
 Nocturia −0.041 0.808 −0.352 0.032 −0.145 0.391 −0.062 0.716 0.161 0.340 0.080 0.640 −0.056 0.743
 Incontinence 0.178 0.292 −0.336 0.042 −0.009 0.957 −0.209 0.214 0.250 0.130 0.206 0.221 0.068 0.687
 Pads 0.123 0.468 −0.253 0.131 0.068 0.689 0.125 0.461 0.298 0.073 0.202 0.230 0.156 0.357
 Voided Volume 0.186 0.271 −0.170 0.314 −0.074 0.663 0.269 0.108 0.205 0.223 0.161 0.340 0.177 0.294
\